Immunomic Therapeutics, Inc. (“ITI”), a privately held clinical-stage biotechnology company pioneering nucleic acid-based immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has cleared ITI’s Investigational New Drug (IND) application for ITI-5000. This clearance allows ITI to initiate the first-in-human clinical trial evaluating ITI-5000, a UNITE®-based self-amplifying RNA vaccine, as monotherapy and in combination with pembrolizumab (Keytruda®), in patients with Sta

The European Commission approved Bayer's higher-dose version of Eylea (aflibercept) for the treatment of patients with visual impairment due to macular oedema following retinal vein occlusion (RVO) including branch, central and hemiretinal vein occlusion. The clearance, announced Friday, marks the third indication for the 8-mg formulation of the VEGF inhibitor. The EU approval "expands the range of retinal indications for Eylea 8 mg – now encompassing wet age-related macular degeneration, diabe

Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next steps Jan. 16, 2026 -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to begin APTN-101, the Company’s Brain Bispecific T cell Engager (BRiTE), yields precise and potent anti-tumor activity by redirecting T cells to bind and destroy cancer cells in the brain Dose-response efficacy and favorable safety profile observed by Duke University scientists in preclinical studies Jan. 20, 2026 -- Adaptin Bio, Inc. (“Adaptin” or the “Com

Jan. 20, 2026 -- Tanabe Pharma America, Inc., the wholly owned subsidiary of Tanabe Pharma Corporation, today announced positive topline efficacy and safety results from the global Phase 3 clinical trial, also known as the INSPIRE study, of investigational dersimelagon (MT-7117), a selective melanocortin-1 receptor (MC1R) agonist, being developed for the oral treatment of adult and adolescent patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). EPP and XLP are ra

Jan. 16, 2026 -- Curonix LLC, a leading medical technology company dedicated to relieving chronic pain, today announced the commercial availability of the Freedom® PNS System for the treatment of chronic craniofacial pain. Freedom PNS is now the first and only PNS System in the United States available for this indication and supported by data from an FDA-approved Investigational Device Exemption (IDE) clinical study, allowing a greater patient population to benefit from PNS therapy. Craniofaci

Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk Norovirus-specific IgA in infant stool correlated with breast milk IgA, suggesting passive transfer of immunity to breastfed infants and the potential for a new approach to confer mucosal anti-norovirus immunity to a vulnerable population Jan. 15, 2026 -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range

Jan. 15, 2026 -- HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering the development of personalized therapies powered by predictive genetic selection tools, presented new data from its Phase 2b OLIVE trial at the American College of Neuropsychopharmacology (ACNP) Annual Meeting on January 14, 2026, in Atlantis, Bahamas. Dr. Hans Eriksson, Chief Medical Officer, presented clinical findings from the OLIVE Phase 2b trial, which evaluated BH-200 (neliva

Jan. 14, 2026 -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the upcoming American Association for Cancer Research (AACR) 2026 Annual Meeting. This prestigious conference will be held April 17 to 22, 2026, in San Diego, California. Organized by the American Association for Cancer Research, this premier event gathers scientists, clinicians, and industry leaders from around the

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cash runway into Q3 2026 Jan. 15, 2026 -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the submission of an